Fraquania Freeman
Primary Care · Tyler, TXNPI 1821499682
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 256 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,463, 2.2 times the $676 reported in 2021. Among primary care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$892
- Livanova USA, Inc.$626
- UCB, Inc.$546
- AbbVie$462
- Pfizer$289
- EMD Serono, Inc.$274
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,10698%
- Education$1252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 47 | $892 |
| Livanova USA, Inc. | 24 | $626 |
| UCB, Inc. | 29 | $546 |
| AbbVie(2 entities) | 27 | $462 |
| Pfizer | 17 | $289 |
| EMD Serono, Inc. | 9 | $274 |
| Lundbeck LLC | 11 | $247 |
| Biogen | 13 | $229 |
| Novartis | 12 | $217 |
| Argenx US, Inc. | 6 | $159 |
| Eisai Inc. | 6 | $145 |
| Genentech USA, Inc. | 7 | $139 |
| Jazz Pharmaceuticals Inc. | 5 | $100 |
| Sumitomo Pharma America, Inc. | 5 | $95 |
| Neurocrine Biosciences, Inc. | 3 | $82 |
| Amgen | 2 | $57 |
| Sanofi | 2 | $55 |
| Bristol Myers Squibb | 3 | $51 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Monteris Medical Corporation | 2 | $49 |
| Neurelis, Inc. | 2 | $48 |
| Catalyst Pharmaceuticals, Inc. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Lilly USA, LLC | 2 | $34 |
| AstraZeneca | 1 | $29 |
| Merz Pharmaceuticals, LLC | 1 | $27 |
| Cycle Pharmaceuticals Inc | 1 | $26 |
| Tanabe Pharma America, Inc. | 1 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Averitas Pharma Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Corium, LLC | 1 | $16 |
| Immedica Pharma US, Inc. | 1 | $14 |
| GE HealthCare | 1 | $14 |
| Avion Pharmaceuticals | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,231 in reported general payments places this provider in the 95th percentile of 563 primary care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 35 | $207,167 |
| NayzilamMidazolam | 19 | $51,804 |
| BriviactBrivaracetam | 31 | $50,974 |
| XcopriCenobamate | 24 | $48,107 |
| VimpatLacosamide | 27 | $44,742 |
| Lacosamide | 130 | $17,283 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 20 | $15,628 |
| Emgality PenGalcanezumab-Gnlm | 16 | $11,354 |
| Clobazam | 45 | $10,645 |
| Levetiracetam | 144 | $9,114 |
| Divalproex Sodium | 57 | $5,199 |
| Lamotrigine ErLamotrigine | 14 | $5,048 |
| Lamotrigine | 221 | $4,946 |
| Memantine Hcl | 99 | $4,099 |
| Oxcarbazepine | 34 | $3,492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Nayzilam, Briviact, Vimpat | $546 | $147,51977 claims |
| SK Life Science, Inc.Xcopri | $892 | $48,10724 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $25 | $1,47823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 563 primary care providers in Texas.
Other primary care in Tyler
- Mary GibbensHouston$42K
- Phillip GulleySan Antonio$23K
- Herbert BautistaDallas$14K
- Brandi JoynerLongview$12K
- Steven ParisAustin$10K
- Hope OdomCollege Station$10K
- Arlena GraysTomball$9K
- Charlotte BallardSan Antonio$9K
- Hannah LancasterMcKinney$9K
- Jacqueline MilesGrand Prairie$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.